Fortrea Holdings Inc. FTRE
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- +21.45%
- 1 year
- +107.02%
- Market cap
- 2.02B
- Revenue (ttm)
- 2.67B
- Profit margin
- -2.58%
- EPS (ttm)
- -0.73
- Shares out
- 96.50M
- Forward P/E
- 18.72
- YTD return
- +21.45%
- 1-year return
- +107.02%
- Volume
- 1.58M
- Avg volume
- 1.63M
- Open
- 19.93
- Previous close
- 20.02
- Day's range
- 19.66 – 21.33
- 52-week range
- 8.55 – 26.16
- Beta
- 1.86
- Analysts
- Buy
- Price target
- 23.63 (+12.8%)
- Earnings date
- Feb 25, 2027
1m +1.14 (+5.75%)
Key statistics
- Enterprise value
- 2.83B
- PEG ratio
- 0.34
- Price / sales
- 0.76
- Price / book
- 3.80
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -1.40%
- Free cash flow
- 250.69M
- Total cash
- 220.60M
- Total debt
- 1.12B
- Return on equity
- -12.34%
- Short % of float
- 9.32%
- 50-day average
- 20.31
- 200-day average
- 15.72
Analyst view
Consensus: buy
- Target (low)
- 13.50
- Target (mean)
- 23.63
- Target (high)
- 29.00
- Strong buy1
- Buy6
- Hold4
- Sell1
- Strong sell1
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate 0.19845.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | 0.19 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 0.2172 | 0.28 | +0.06 | +28.91% |
| Jul 29, 2026 | Jun 30, 2026 | 0.1804 | 0.23 | +0.05 | +27.49% |
| May 5, 2026 | Mar 31, 2026 | 0.03 | 0.16 | +0.13 | +433.33% |
| Feb 26, 2026 | Dec 31, 2025 | 0.16 | 0.09 | -0.07 | -43.75% |
| Nov 5, 2025 | Sep 30, 2025 | 0.16 | 0.12 | -0.04 | -25.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | TD Cowen | main | Buy | Buy |
| Oct 30, 2026 | Citigroup | main | Buy | Buy |
| Oct 30, 2026 | Truist Securities | main | Buy | Buy |
| Oct 30, 2026 | Barclays | main | Overweight | Overweight |
| Oct 30, 2026 | Evercore ISI Group | main | Outperform | Outperform |
| Oct 20, 2026 | UBS | main | Neutral | Neutral |
About Fortrea Holdings Inc.
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- fortrea.com
News
TD Cowen Maintains Buy on Fortrea Holdings, Raises Price Target to $26 
Citigroup Maintains Buy on Fortrea Holdings, Raises Price Target to $27 
Truist Securities Maintains Buy on Fortrea Holdings, Raises Price Target to $29 - Barclays Maintains Overweight on Fortrea Holdings, Raises Price Target to $26
- Evercore ISI Group Maintains Outperform on Fortrea Holdings, Raises Price Target to $28
What Fortrea (FTRE) Said on Its Q3 Earnings Call 
Fortrea Holdings Inc. (FTRE) Q3 2026 Earnings Call Transcript 
Fortrea Holdings Q3 2026 Earnings Call Transcript 
Fortrea Holdings Inc. (FTRE) Q3 Earnings and Revenues Surpass Estimates 
Fortrea Holdings Raises FY2026 Sales Guidance from $2.620B-$2.690B to $2.665B-$2.690B vs $2.663B Est
Your note
Sign in to keep a note on FTRE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| MCCONNELL JILL G | Chief Financial Officer | Sale | Jun 1, 2026 | 78,416 |
| MORAIS MARK A | Chief Operating Officer | Sale | Sep 8, 2026 | 86,419 |
| NEUPERT PETER M | Director | Conversion of Exercise of derivative security | May 13, 2026 | 246,668 |
| PESICKA EDWARD A | Director | Conversion of Exercise of derivative security | Jun 9, 2026 | 52,453 |
| PIKE THOMAS | Chief Executive Officer | Sale | Jan 12, 2025 | 159,868 |
| RAY AMRIT | Director | Conversion of Exercise of derivative security | Jun 9, 2026 | 52,453 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 16.37% | 15,799,104 | 330.99M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 8.72% | 8,414,011 | 176.27M | Jun 29, 2026 |
| Sessa Capital IM, L.P. | 4.76% | 4,593,550 | 96.23M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.33% | 4,181,552 | 87.60M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 3.96% | 3,816,627 | 79.96M | Jun 29, 2026 |
| State Street Corporation | 3.92% | 3,784,173 | 79.28M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.87% | 5,659,969 | 118.58M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.11% | 3,000,631 | 62.86M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.59% | 2,497,468 | 52.32M | Sep 29, 2026 |
| Fidelity Capital Trust-Fidelity Value Fund | 2.37% | 2,290,800 | 47.99M | Aug 30, 2026 |
| LOOMIS SAYLES FUNDS II-Loomis Sayles Small Cap Growth Fund | 1.37% | 1,319,079 | 27.63M | Jun 29, 2026 |
| Columbia Acorn Trust-Columbia Acorn Fund | 1.34% | 1,291,989 | 27.07M | Jun 29, 2026 |